Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.21
$2.06
$4.50
$370.71M1.181.50 million shsN/A
Savara Inc. stock logo
SVRA
Savara
$2.14
+1.7%
$2.58
$1.89
$5.11
$378.51M0.311.27 million shs1.11 million shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
$3.23
N/A0.98949,778 shsN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
$5.90
-1.4%
$6.28
$2.36
$7.48
$697.89M0.461.43 million shs993,025 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+6.23%+95.41%
Savara Inc. stock logo
SVRA
Savara
0.00%-3.39%-10.29%-25.09%-50.69%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%-96.41%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
0.00%+4.91%-12.52%-2.55%+120.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.4639 of 5 stars
1.20.00.04.21.30.00.0
Savara Inc. stock logo
SVRA
Savara
2.206 of 5 stars
3.31.00.00.01.43.30.6
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.2792 of 5 stars
4.71.00.00.03.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60162.30% Upside
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3.30
Buy$20.88254.05% Upside

Current Analyst Ratings Breakdown

Latest SVRA, CKPT, TRVI, and TFFP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/2/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
5/28/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$21.00
5/20/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/8/2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$730K0.40N/AN/A$4.04 per share0.02
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/A$1.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.44N/AN/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$47.91M-$0.45N/AN/AN/AN/A-58.41%-52.52%8/6/2025 (Estimated)

Latest SVRA, CKPT, TRVI, and TFFP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
5/6/2025Q1 2025
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
-$0.13-$0.09+$0.04-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/A
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
N/A
15.38
15.38

Institutional Ownership

CompanyInstitutional Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
Savara Inc. stock logo
SVRA
Savara
87.93%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
15.25%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
95.76%

Insider Ownership

CompanyInsider Ownership
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
Savara Inc. stock logo
SVRA
Savara
5.13%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
4.50%
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
Savara Inc. stock logo
SVRA
Savara
20172.84 million163.97 millionOptionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionOptionable
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
20117.29 million95.83 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Predicts TRVI FY2025 Earnings
Analysts Offer Predictions for TRVI FY2025 Earnings
TRVI Trevi Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)
As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Savara stock logo

Savara NASDAQ:SVRA

$2.13 +0.04 (+1.67%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.19 +0.06 (+2.81%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

$0.06 0.00 (0.00%)
As of 04/10/2025

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Trevi Therapeutics stock logo

Trevi Therapeutics NASDAQ:TRVI

$5.90 -0.08 (-1.40%)
As of 07/3/2025 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.